3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Sezary Syndrome
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Carcinoma, Hepatocellular
1
Interventions
zanolimumab
3
mogamulizumab
3
denileukin diftitox
2
Vorinostat
2
Vitamin B 12
2
Panobinostat
2
Folic Acid
2
10-propargyl-10-deazaaminopterin
2
resminostat
1
ontuxizumab
1
navitoclax
1
N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
1
MAC-ST-001
1
Interleukin-12 Subunit p35
1
Fentanyl
1
Fenretinide
1
Duration of Therapy
1
Bexarotene
1
A-dmDT390-bisFv(UCHT1) protein
1
(N(1),N(12))bis(ethyl)-6,7-dehydrospermine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Sezary Syndrome
×
resminostat
×
Clear all
NCT02953301
2024-08-30
RESMAIN
4SC AG
Phase 2
Completed
201 enrolled